Andreas Rentz/Getty Images News
- Bayer (OTCPK:BAYZF) will invest 400M Euros ($462.7M) to expand a contraceptive product manufacturing site in Finland and construct a new one in Costa Rica for low and middle-income countries.
- The investment will boost production of hormonal implants and hormonal intrauterine systems to meet global demand for long-acting reversible contraceptives.
- The United Nations Population Fund and the United States Agency for International Development is partnered with Bayer on the plans.
- Bayer (OTCPK:BAYRY +1.8%) has a goal of providing 100M women and girls with access to family planning by 2030.
- Last month, Bayer's refractory chronic cough treatment eliapixant (BAY1817080) met its main goal in a mid-stage trial.